- Home
- RIGL vs OPK Comparison
RIGL vs OPK Comparison
Compare RIGL & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RIGL | OPK |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 884.9M | 1.0B |
| IPO Year | 2000 | 2011 |
Fundamental Metrics
Financial Performance| Metric | RIGL | OPK |
|---|---|---|
| Price | $45.86 | $1.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 3 |
| Target Price | ★ $45.67 | $1.60 |
| AVG Volume (30 Days) | 206.3K | ★ 2.6M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 1.32 | N/A |
| Revenue | $294,282,000.00 | ★ $606,879,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | $4.24 |
| P/E Ratio | $34.00 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $24.84 | $0.98 |
| 52 Week High | $52.24 | $1.73 |
Technical Indicators
Market Signals| Indicator | RIGL | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 59.72 |
| Support Level | $40.05 | $1.12 |
| Resistance Level | $49.50 | $1.73 |
| Average True Range (ATR) | 1.45 | 0.07 |
| MACD | -0.61 | -0.00 |
| Stochastic Oscillator | 17.89 | 52.73 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About OPK OPKO Health Inc.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.